Manipal Hospitals Sarjapur Road hosted a session on HoLEP for Benign Prostatic Hyperplasia. This innovative technique, led by ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with ...

MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat ...

PRNewswire Bangalore Karnataka [India] January 15 Manipal Hospitals Sarjapur Road recently hosted an awareness session on ...

Of the agents that interfere with testosterone's stimulatory effect on prostate size, finasteride, a 5-α-reductase inhibitor, is the only one with FDA-approved labeling for BPH treatment.

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

Winter leads to an increased risk of problems related to the prostate gland in seniors. Cold weather causes urinary and ...

Treatment with vibegron reduced the average ... males on pharmacological therapy for benign prostatic hyperplasia (BPH). The approval was based on data from the randomized, double-blind, placebo ...

How your doctor treats you depends on your age, health, the size of your prostate, and how BPH affects you. If your symptoms don't bother you too much, you can put off treatment and see how you feel.

We are excited to reach this important milestone in the Expander-2 Pivotal Trial,” said Paul Edwards, President and CEO of Prodeon Medical. “Completing enrollment is a key step in our mission to ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.